Axcella misses primary endpoint in long COVID trial but plots path to market based on fatigue scores Genentech-AC Immune's Alzheimer's drug failed, but what have they learned from crenezumab? AbbVie gives Sosei a StaRring role in neurological drug discovery plans, paying $40M and committing $1.2B IDRx launches with $122M to develop combo therapy that addresses precision medicine 'whack-a-mole' Kazia dropped from global umbrella trial to treat aggressive form of brain cancer Stealth handed cloaking device as go-private merger with Morningside advances Less than two weeks after failure-induced stock shock, VBL Therapeutics lays off staff Lower abdominal fat and cardiovascular risk? Alnylam thinks it found a gene for that As pharma's NASH failures pile up, Regeneron thinks its found the target that matters In search of Alzheimer's drug targets, Allen Institute builds massive brain cell map Crown Bioscience rejigs executive team and plans global expansion Clario joins workplace diversity, equity and inclusion movement Regeneron puts kibosh on 4 antibody studies as Pfizer's Paxlovid dominates the COVID treatment scene Featured Story | By Nick Paul Taylor Axcella’s phase 2a long COVID clinical trial has missed its primary endpoint. But with the study linking the drug to improved fatigue scores versus placebo, the biotech plans to meet with regulators to discuss its path to a registration trial. read more |
| |
|---|
|
Top Stories By Annalee Armstrong Roche’s Genentech and AC Immune know they have a failed trial on their hands for the Alzheimer’s disease drug crenezumab. But the partners are still parsing through the data, trying to find signals that could inform the next wave of development in the neurodegenerative disease. read more By Nick Paul Taylor AbbVie is tightening its ties to Sosei Heptares. Two years after forming an inflammatory and autoimmune pact with Sosei, AbbVie is paying $40 million and committing up to $1.2 billion in milestones to expand its relationship with the GPCR specialist into neurological diseases. read more By Max Bayer Alexis Borisy, co-founder of EQRx and Relay Therapeutics, is launching yet another biotech, this time aimed at addressing the "whack-a-mole" pitfalls of precision medicine in oncology. His new venture, IDRx, has raised $122 million to develop a one-two punch combo therapy that's first slated to target gastrointestinal cancer. read more By Max Bayer Kazia Therapeutics has been dropped from a global adaptive clinical trial to find new treatments for an aggressive form of brain cancer. The company said it did not meet "pre-specified criteria" to advance in the trial, which the trial record defines as a specific efficacy threshold. read more By Annalee Armstrong Stealth BioTherapeutics has officially been handed its cloaking device thanks to a merger agreement signed with Morningside Venture (I) Investments that will take the mitochondrial dysfunction biotech private once again. read more By Max Bayer VBL Therapeutics is trimming its workforce by 35% less than two weeks after its lead asset failed a phase 3 trial. The remainder of the company's pipeline remains in question after the failure sent the company's shares spiraling. read more By James Waldron Who doesn’t want reduced abdominal fat and a lower risk of cardiovascular disease? Well, Alnylam Pharmaceuticals thinks it’s identified the gene mutation that makes this fitness instructor’s dream a reality. read more By Max Bayer Researchers from the Regeneron Genetic Center recently released a new study indicating how mutations to one specific gene were protective against liver disease including nonalcoholic steatohepatitis (NASH). The findings come as Pfizer added to list of pharmas that have seen their NASH dreams dashed in the clinic. read more By Angus Liu The Allen Institute and its collaborators are drawing a comprehensive map of cellular and molecular changes during the development of Alzheimer’s, hoping to identify new targets for future therapies. And they have released the first findings. read more By Gareth Macdonald Crown Bioscience has restructured its leadership team and hinted at acquisitions in the U.S. and Europe. read more By Joseph Keenan Clario, a clinical trial tech firm, pledged its commitment to increase workplace equality by joining the CEO Action for Diversity and Inclusion workplace movement. read more By Fraiser Kansteiner Regeneron Pharmaceuticals—whose antibody cocktail REGEN-COV once helped form the vanguard of COVID-19 therapeutics—has axed a clutch of trials weighing the med across a range of patients and clinical stages. read more Resources Sponsored by: Speid & Associates, Inc. The total immersion, transformative training will take place at the Harvard Club in Boston. VIRTUAL in real time is also available. Contingencies for COVID19 will apply. Register NOW for a large early bird discount www.drugstomarket.com/drugbootcamp. Sponsored by: Thermo Fisher Scientific See how integration of innovative genetic analysis techniques into drug development is driving biopharma & biotech companies ahead. Sponsored by: Triangle Insights Group, LLC Discover how the new partnership between TrialCard and Triangle Insights Group can help you bridge the critical gap between strategy and execution, ensuring commercialization success of your product or therapy. Sponsored by: Nexelis Discover Nexelis’ first-hand perspective on how to develop innovative, agile solutions in vaccine efficacy testing in this exclusive e-book. Sponsored by: Catalent What is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent Learn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent How can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent Carla Vozone discusses the significant trends in the OINDP segment including large molecules and novel indications, changes within CDMOs and various challenges facing the industry. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Ypsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Fierce Biotech Cell & Gene Therapy Forum October 19, 2022 | Free Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ | 